PL336803A1 - Analogues of peptidic parathyroid hormone - Google Patents
Analogues of peptidic parathyroid hormoneInfo
- Publication number
- PL336803A1 PL336803A1 PL98336803A PL33680398A PL336803A1 PL 336803 A1 PL336803 A1 PL 336803A1 PL 98336803 A PL98336803 A PL 98336803A PL 33680398 A PL33680398 A PL 33680398A PL 336803 A1 PL336803 A1 PL 336803A1
- Authority
- PL
- Poland
- Prior art keywords
- peptidic
- analogues
- parathyroid hormone
- parathyroid
- hormone
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 108090000445 Parathyroid hormone Proteins 0.000 title 1
- 239000000199 parathyroid hormone Substances 0.000 title 1
- 229960001319 parathyroid hormone Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4647297P | 1997-05-14 | 1997-05-14 | |
| PCT/US1998/009843 WO1998051324A1 (en) | 1997-05-14 | 1998-05-13 | Peptide parathyroid hormone analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL336803A1 true PL336803A1 (en) | 2000-07-17 |
Family
ID=21943653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98336803A PL336803A1 (en) | 1997-05-14 | 1998-05-13 | Analogues of peptidic parathyroid hormone |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6472505B1 (https=) |
| EP (1) | EP0986395A4 (https=) |
| JP (1) | JP2001517957A (https=) |
| KR (1) | KR100351213B1 (https=) |
| CN (1) | CN1261281A (https=) |
| AP (1) | AP9901686A0 (https=) |
| AU (1) | AU746461B2 (https=) |
| BG (1) | BG103957A (https=) |
| BR (1) | BR9808786A (https=) |
| CA (1) | CA2290443A1 (https=) |
| EA (1) | EA002819B1 (https=) |
| HU (1) | HUP0003349A3 (https=) |
| IL (1) | IL132901A0 (https=) |
| NO (1) | NO995568L (https=) |
| OA (1) | OA11216A (https=) |
| PL (1) | PL336803A1 (https=) |
| SK (1) | SK151599A3 (https=) |
| UA (1) | UA62967C2 (https=) |
| WO (1) | WO1998051324A1 (https=) |
| ZA (1) | ZA984077B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20003798A3 (cs) | 1998-04-15 | 2001-08-15 | Aventis Pharmaceuticals Products, Inc. | Způsob výroby cyklických peptidů vázaných k polymernímu nosiči |
| US6316410B1 (en) * | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| AU2003233286A1 (en) * | 2002-05-16 | 2003-12-02 | Theratechnologies Inc. | Pth derivatives resistant to skin proteases |
| WO2004073587A2 (en) * | 2003-02-19 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1) |
| AU2004257362A1 (en) * | 2003-07-15 | 2005-01-27 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| US7439226B2 (en) * | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
| CA2567056A1 (en) * | 2004-05-10 | 2005-12-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| US9051379B2 (en) | 2005-07-07 | 2015-06-09 | Fulcrum Sp Ltd. | Sp1 polypeptides, modified Sp1 polypeptides and uses thereof |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| BRPI0719885B8 (pt) * | 2006-10-13 | 2021-05-25 | Lilly Co Eli | peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição. |
| EP2391377A2 (en) | 2009-02-02 | 2011-12-07 | Ramot at Tel-Aviv University Ltd. | Peptides, pharmaceutical compositions comprising same and uses thereof |
| AU2010231514A1 (en) | 2009-04-01 | 2011-11-03 | Rappaport Family Institute For Research In The Medical Sciences | A method of regulating proliferation and differentiation of keratinocytes |
| WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
| US20120070449A1 (en) | 2009-05-28 | 2012-03-22 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
| US8999932B2 (en) | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| BR112012013725A2 (pt) | 2009-12-07 | 2017-01-10 | Univ Michigan Tech | paratormônio de urso preto e métodos de usar o paratormônio de uso preto. |
| US9352000B2 (en) | 2010-05-05 | 2016-05-31 | Rappaport Family Institute For Research In The Medical Sciences | Use of CCL1 in therapy |
| MX358161B (es) * | 2010-05-13 | 2018-08-06 | The General Hospital Corp Star | Analogos de hormona paratiroidea y usos para los mismos. |
| WO2012017439A2 (en) | 2010-08-04 | 2012-02-09 | Ramot At Tel-Aviv University Ltd. | Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
| WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
| EP2721686B1 (en) * | 2011-06-17 | 2018-11-28 | NantEnergy, Inc. | Ionic liquid containing sulfonate ions |
| CA2866358C (en) | 2012-03-06 | 2020-06-23 | Cellect Biotechnology Ltd. | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof |
| US9695402B2 (en) | 2013-09-17 | 2017-07-04 | Yeda Research And Development Co. Ltd. | ERK-derived peptides and uses thereof |
| US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
| EP3122768A2 (en) | 2014-03-27 | 2017-02-01 | Yeda Research and Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
| US20180036382A1 (en) | 2015-02-09 | 2018-02-08 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| EP3261582B1 (en) | 2015-02-26 | 2021-01-06 | Remodeless CV Ltd. | Methods and compositions relating to leptin antagonists |
| US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
| WO2017122209A2 (en) | 2016-01-12 | 2017-07-20 | Yeda Research And Development Co. Ltd. | NF-kappaB INHIBITORS |
| IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
| IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
| US11820833B2 (en) | 2016-06-05 | 2023-11-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Peptides that inhibit binding of EPCR to its ligand to treat inflammation |
| WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
| KR20190091192A (ko) | 2016-12-01 | 2019-08-05 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 신경 손상의 병용 치료제 |
| WO2018185768A1 (en) | 2017-04-07 | 2018-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Hair care compositions |
| WO2018216011A1 (en) | 2017-05-23 | 2018-11-29 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
| EP3655009B1 (en) | 2017-07-20 | 2023-10-11 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Nanoparticle compositions |
| IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
| IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
| IL274979B2 (en) | 2017-11-29 | 2024-07-01 | Univ Ramot | Methods for the prevention and treatment of neurogenic seizures |
| JP7350019B2 (ja) | 2018-05-31 | 2023-09-25 | イミュニティ ファルマ リミテッド | 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法 |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Type II stable opsins and methods of using them |
| IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
| IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| KR20220151168A (ko) | 2020-02-09 | 2022-11-14 | 엔엘씨 파르마 엘티디 | Sars-cov-2에 대한 신속한 검출 테스트 |
| EP4114473A1 (en) | 2020-03-05 | 2023-01-11 | Ariel Scientific Innovations Ltd. | Anti-hemorrhaging compositions |
| US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
| WO2022064494A2 (en) | 2020-09-23 | 2022-03-31 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating coronaviral infections |
| EP4225903A1 (en) | 2020-10-07 | 2023-08-16 | Protalix Ltd. | Long-acting dnase |
| MX2023005235A (es) | 2020-11-03 | 2023-10-16 | Protalix Ltd | Uricasa modificada y usos de la misma. |
| IL305315A (en) | 2021-02-18 | 2023-10-01 | Yeda res & development co ltd | Methods for producing vaccines |
| IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
| WO2023031934A1 (en) | 2021-09-02 | 2023-03-09 | Yeda Research And Development Co. Ltd. | Agents that target the glycine arginine-rich domain of nucleolin and uses thereof |
| WO2024038462A1 (en) | 2022-08-17 | 2024-02-22 | Yeda Research And Development Co. Ltd. | Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor |
| WO2024241314A1 (en) | 2023-05-22 | 2024-11-28 | Neomanna Ltd | Black soldier fly protein extracts |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US4423037A (en) | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
| US4427827A (en) | 1982-10-20 | 1984-01-24 | Usv Pharmaceutical Corporation | Synthesis of hormone fragments |
| FR2550204B1 (fr) * | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
| US4771124A (en) | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
| CA2040264A1 (en) | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
| CA2087087C (en) | 1992-01-22 | 2000-07-18 | Burton H. Sage, Jr. | Molecules for iontophoretic delivery |
| US5434246A (en) | 1992-03-19 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
| US5814603A (en) | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| CA2098639A1 (en) | 1992-06-19 | 1993-12-20 | K. Anne Kronis | Bone stimulating, non-vasoactive parathyroid hormone variants |
| US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| EP0679088B1 (en) | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| CO4410206A1 (es) | 1994-07-28 | 1997-01-09 | Sandoz Ag | DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN |
| DE19508672A1 (de) * | 1995-03-10 | 1996-09-12 | Boehringer Mannheim Gmbh | Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US5717062A (en) * | 1995-06-07 | 1998-02-10 | Beth Israel Hospital Association | Cyclic analogs of PTH and PTHrP |
| DE69629758T2 (de) | 1995-06-07 | 2004-06-03 | Compaq Computer Corp., Houston | Verfahren und Vorrichtung für die Überwachung des Datenflusses in einem fehlertoleranten Multiprozessorsystem |
| US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
| DK0915911T3 (da) * | 1996-08-02 | 2004-03-08 | Ca Nat Research Council | Analoger til parathyreoideahormon til behandling af osteoporose |
-
1998
- 1998-05-13 HU HU0003349A patent/HUP0003349A3/hu unknown
- 1998-05-13 CA CA002290443A patent/CA2290443A1/en not_active Abandoned
- 1998-05-13 CN CN98806651A patent/CN1261281A/zh active Pending
- 1998-05-13 EP EP98921200A patent/EP0986395A4/en not_active Withdrawn
- 1998-05-13 IL IL13290198A patent/IL132901A0/xx unknown
- 1998-05-13 PL PL98336803A patent/PL336803A1/xx unknown
- 1998-05-13 UA UA99126574A patent/UA62967C2/uk unknown
- 1998-05-13 KR KR1019997010523A patent/KR100351213B1/ko not_active Expired - Fee Related
- 1998-05-13 JP JP54953698A patent/JP2001517957A/ja not_active Ceased
- 1998-05-13 AU AU73867/98A patent/AU746461B2/en not_active Ceased
- 1998-05-13 WO PCT/US1998/009843 patent/WO1998051324A1/en not_active Ceased
- 1998-05-13 EA EA199901025A patent/EA002819B1/ru not_active IP Right Cessation
- 1998-05-13 SK SK1515-99A patent/SK151599A3/sk unknown
- 1998-05-13 BR BR9808786-0A patent/BR9808786A/pt not_active Application Discontinuation
- 1998-05-13 AP APAP/P/1999/001686A patent/AP9901686A0/en unknown
- 1998-05-14 ZA ZA984077A patent/ZA984077B/xx unknown
-
1999
- 1999-01-12 US US09/228,990 patent/US6472505B1/en not_active Expired - Fee Related
- 1999-11-12 OA OA9900247A patent/OA11216A/en unknown
- 1999-11-12 NO NO995568A patent/NO995568L/no not_active Application Discontinuation
- 1999-12-06 BG BG103957A patent/BG103957A/bg unknown
-
2002
- 2002-03-13 US US10/097,079 patent/US20020132973A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA002819B1 (ru) | 2002-10-31 |
| AP9901686A0 (en) | 1999-12-31 |
| EP0986395A4 (en) | 2004-12-01 |
| HUP0003349A3 (en) | 2001-12-28 |
| NO995568L (no) | 1999-12-29 |
| AU7386798A (en) | 1998-12-08 |
| WO1998051324A1 (en) | 1998-11-19 |
| US20020132973A1 (en) | 2002-09-19 |
| CA2290443A1 (en) | 1998-11-19 |
| NO995568D0 (no) | 1999-11-12 |
| BG103957A (bg) | 2000-04-28 |
| OA11216A (en) | 2003-07-10 |
| JP2001517957A (ja) | 2001-10-09 |
| ZA984077B (en) | 1998-11-24 |
| BR9808786A (pt) | 2000-07-11 |
| CN1261281A (zh) | 2000-07-26 |
| IL132901A0 (en) | 2001-03-19 |
| EA199901025A1 (ru) | 2000-06-26 |
| AU746461B2 (en) | 2002-05-02 |
| KR20010012568A (ko) | 2001-02-15 |
| UA62967C2 (en) | 2004-01-15 |
| EP0986395A1 (en) | 2000-03-22 |
| HUP0003349A2 (hu) | 2001-01-29 |
| US6472505B1 (en) | 2002-10-29 |
| SK151599A3 (en) | 2000-09-12 |
| KR100351213B1 (ko) | 2002-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL336803A1 (en) | Analogues of peptidic parathyroid hormone | |
| HUP9904596A3 (en) | Analogs of parathyroid hormone | |
| HUP9901718A3 (en) | Analogs of parathyroid hormone | |
| LT99010A (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
| LT99052A (en) | Heptapeptide oxytocin analogues | |
| PL345583A1 (en) | Peptide analogues of pacap | |
| IL134596A0 (en) | Growth hormone secretagogues | |
| IL121391A0 (en) | Synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide | |
| FI990126L (fi) | Paratyreoideahormonianalogeja osteoporoosin hoitoon | |
| IL110018A0 (en) | Biologically active vasopressin analogues | |
| HUP0001477A3 (en) | Calcitonin receptor-binding peptides | |
| PL339085A1 (en) | Recombinative expression of insulin peptide c | |
| ZA981419B (en) | Arylsulfonamides and analogues | |
| GB9718110D0 (en) | Peptides | |
| GB9700154D0 (en) | Peptides | |
| GB9714276D0 (en) | Peptides and related compounds | |
| EP0779813A4 (en) | PHOSPHONATES AND PARATHORMON AGAINST OSTEOPOROSE | |
| IL135050A0 (en) | Insulin-like polypeptide and uses therefor | |
| HU0600009D0 (en) | Analogs of parathyroid hormone | |
| GB2309224B (en) | Tamoxifen and analogues thereof | |
| GB2327673B (en) | Tamoxifen and analogues thereof | |
| AUPO528097A0 (en) | Protease resistant analogues of calcitonin | |
| ZA965886B (en) | Analogs of parathyroid hormone | |
| AUPM782594A0 (en) | Protease resistant analogues of calcitonin | |
| ZA974780B (en) | Intermediates for the preparation of peptide analogues. |